Verrica Pharmaceuticals Inc (VRCA) Stock Analysis
Verdict: HOLD
First-mover YCANTH scaling and heavy insider buying signal a turnaround, but aggressive dilution risk remains the primary hurdle.
Investment score: 64/100
Analysis as of
Is Verrica Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
The model sees a high-conviction recovery play backed by institutional-grade gross margins and aggressive insider positioning.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 90/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Verrica Pharmaceuticals Inc opportunities and risks
What speaks for VRCA
- YCANTH Commercial Scaling
What speaks against VRCA
- Equity Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| VRCA | n/a | 1.6x | n/a | 89.5% | -48.0% | -24.0% |
| RFL | n/a | 106.1x | n/a | 84.4% | -3321.7% | -30.8% |
| RANI | n/a | 16.1x | n/a | 94.9% | -929.1% | -33.5% |
| CGTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -21.3% |
| NTHI | n/a | 0.0x | n/a | 0.0% | 0.0% | -23.8% |
| CWEB.TO | n/a | 0.8x | n/a | 42.4% | -75.1% | -36.0% |
| Peer median | n/a | 0.8x | n/a | 42.4% | -75.1% | -30.8% |
Frequently asked questions about Verrica Pharmaceuticals Inc (VRCA)
Is VRCA stock a good investment?
The TradeMates model rates Verrica Pharmaceuticals Inc as HOLD with an investment score of 64/100. The model sees a high-conviction recovery play backed by institutional-grade gross margins and aggressive insider positioning. This is algorithmic model output, not personal investment advice.
Is VRCA stock a buy?
The TradeMates model verdict for VRCA is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.